| |  Online-Ressource |
|---|
| Verfasst von: | Krug, David [VerfasserIn]  |
|---|
| | Tio, Joke [VerfasserIn] |
|---|
| | Abaci, Ali [VerfasserIn] |
|---|
| | Beurer, Björn Michael [VerfasserIn] |
|---|
| | Brügge, Sandra [VerfasserIn] |
|---|
| | Elsayad, Khaled [VerfasserIn] |
|---|
| | Meixner, Eva [VerfasserIn] |
|---|
| | Park-Simon, Tjoung-Won [VerfasserIn] |
|---|
| | Smetanay, Katharina [VerfasserIn] |
|---|
| | Winkelmann, Franziska [VerfasserIn] |
|---|
| | Wittig-Sauerwein, Andrea [VerfasserIn] |
|---|
| | Wöckel, Achim [VerfasserIn] |
|---|
| Titel: | The safety and efficacy of the combination of Sacituzumab Govitecan and palliative radiotherapy |
|---|
| Titelzusatz: | a retrospective multi-center cohort study |
|---|
| Verf.angabe: | David Krug, Joke Tio, Ali Abaci, Björn Beurer, Sandra Brügge, Khaled Elsayad, Eva Meixner, Tjoung-Won Park-Simon, Katharina Smetanay, Franziska Winkelmann, Andrea Wittig and Achim Wöckel |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | 25 April 2024 |
|---|
| Umfang: | 12 S. |
|---|
| Fussnoten: | Gesehen am 14.11.2024 |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 16(2024), 9, Artikel-ID 1649, Seite 1649-1-1649-12 |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | Sacituzumab govitecan (SG) is a new treatment option for patients with metastatic triple-negative and hormone receptor-positive, HER2-negative breast cancer. This antibody-drug conjugate is currently approved as monotherapy. Palliative radiotherapy is frequently used to treat symptomatic metastases locally. Concurrent use of SG and irradiation was excluded in clinical trials of SG, and there are currently limited published data. We report here a systematic review, as well as a retrospective multi-center study of 17 patients with triple-negative breast cancer who received concurrent SG and radiotherapy. In these patients, concurrent use was found to be efficient, safe and well tolerated. There were no apparent differences in moderate or severe acute toxicity according to the timing of SG administration. |
|---|
| DOI: | doi:10.3390/cancers16091649 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/cancers16091649 |
|---|
| | Volltext: https://www.mdpi.com/2072-6694/16/9/1649 |
|---|
| | DOI: https://doi.org/10.3390/cancers16091649 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | antibody-drug conjugate |
|---|
| | brain metastases |
|---|
| | breast cancer |
|---|
| | palliative radiotherapy |
|---|
| | radiosurgery |
|---|
| | stereotactic radiotherapy |
|---|
| K10plus-PPN: | 190875818X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
¬The¬ safety and efficacy of the combination of Sacituzumab Govitecan and palliative radiotherapy / Krug, David [VerfasserIn]; 25 April 2024 (Online-Ressource)
